GE HealthCare Technologies IncNasdaq: GEHC
Health Care · Health Care Equipment
$65.35
+1.58%
Vol: 275K
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21GE HealthCare unveiled AI-powered MR systems at ISMRM 2026 but stock pressured by guidance cut and lawsuitsNegative▶
GE HealthCare on May 11, 2026 announced advancements in MR technology at the ISMRM 2026 annual meeting, including the new SIGNA One AI workflow ecosystem, Sonic DL 2D deep-learning acceleration (FDA 510(k) pending), and SIGNA Studio software collaboration suite. Director Rodney Hochman purchased $100,364 of shares on May 13. However, the stock remains pressured following the Q1 earnings miss, cut full-year EPS guidance, and multiple securities law investigations. GEHC's 30-day return is down 18.62% and YTD return down 26.64%. Adjusted EBIT margin guidance was lowered by 40bps to 15.4%-15.7%. Risk: ongoing legal scrutiny, inflation pressures, and supply chain issues continue to weigh on the stock.
May 20GE HealthCare showcases AI-powered MR systems at ISMRM 2026 amid Q1 margin pressures and lowered guidanceMixed▶
GE HealthCare unveiled next-gen SIGNA MR technology and AI-powered MR systems at the ISMRM 2026 conference on May 11, including integration of icometrix brain MRI analysis and the FDA 510(k)-pending Sonic DL deep-learning acceleration. The product showcase comes amid a difficult stock period — shares are down 26.6% YTD after Q1 revenue of $5.1B with only 2.9% organic growth and management lowering full-year adjusted EBIT margin guidance to 15.4-15.7%. Goldman Sachs cited rising input costs, macro exposure, and tariffs as key concerns. Director Rodney Hochman bought 1,618 shares ($100,364) on May 13 in a vote of confidence. Shareholders backed the board, governance and compensation at the May 11 annual meeting.
May 19GE HealthCare director Rodney Hochman buys $100K in shares and unveils next-gen SIGNA MR technology amid post-earnings investigations.Mixed▶
On May 13, 2026, GE HealthCare director Rodney F. Hochman purchased 1,618 shares for approximately $100,364, signaling insider confidence after a sharp post-earnings drop. On May 11, 2026, the company unveiled next-generation SIGNA MR technologies at ISMRM 2026, including helium-free 1.5T MR and AI-powered Sonic DL for 2D imaging (510(k) pending), which could accelerate up to 85% of MR exams. At the May 7 annual meeting, shareholders elected eight directors, named Hochman independent lead director, and appointed Anne Madden as Nominating chair. However, the company missed Q1 adjusted earnings, cut full-year EPS guidance, and triggered multiple securities-law investigations, with the stock down 18.62% over 30 days and 26.64% YTD. Risk: legal investigations and continued guidance pressure overshadow product innovation.
May 18GE HealthCare unveiled AI-powered MR systems at ISMRM 2026 on May 11 and saw notable May 13 insider buy of 1,618 shares ($100,364) by Director Hochman.Mixed▶
On May 11, 2026, GE HealthCare announced next-gen SIGNA MR systems and AI-powered workflow technologies at the ISMRM 2026 Annual Meeting, including a 510(k)-pending Sonic DL 2D deep-learning acceleration that could benefit up to 85% of MR exams, plus two new MAGNUS head-only research scanner installations at King's College London and West China Hospital. The May 7 annual meeting elected eight directors, ratified Deloitte and named Rodney Hochman lead director. Director Hochman bought 1,618 shares ($100,364) on May 13 and Director Stromberg bought 1,000 shares ($61,689) on May 6. The stock has been under pressure since Q1's guidance cut, with adjusted EBIT margin guide lowered ~40bps to 15.4%-15.7% on inflation, tariffs, a PDx supplier recall and Patient Care Solutions weakness; Goldman Sachs lowered its outlook. Shares closed at $60.76 with a $60.67-$62.64 range on May 16.
May 15GE HealthCare Director Hochman buys $100K of stock May 13 amid ISMRM AI MR product showcaseMixed▶
On May 13, 2026, GE HealthCare Director Rodney F. Hochman disclosed an open-market purchase of 1,618 shares at $62.03 via a family trust, totaling about $100,364. Director William J. Stromberg bought 1,000 shares at $61.69 on May 6. At the May 7 annual meeting, shareholders elected eight directors, ratified Deloitte and approved executive compensation; Hochman was named independent lead director. At ISMRM 2026, GE HealthCare unveiled next-gen SIGNA MR, helium-free 1.5T MR, advanced 3T scanner and AI-powered workflow, and announced two new installations of its MAGNUS prototype head-only MR scanner at King's College London and West China Hospital. Shares trade around $61.30, down 24.5% YTD from $82.02 following an April Q1 guidance cut of $0.15 tied to a $250M tariff and supplier-quality inflation impact. Insider buying signals confidence but tariff/margin pressures persist.
May 14GE HealthCare unveils AI-powered MR systems at ISMRM 2026 with 510(k) pending Sonic DL technologyPositive▶
At ISMRM 2026 on May 11, GE HealthCare unveiled next-gen SIGNA MR technology including helium-free 1.5T MR and AI-powered workflow. Its Sonic DL deep-learning acceleration technique has 510(k) pending FDA status, designed to accelerate up to 85% of MR exams. Two new MAGNUS prototype installations announced at King's College London and West China Hospital. The company will spotlight AI-enabled radiation therapy solutions at ESTRO 2026 (May 12). Director William Stromberg bought 1,000 shares at $61.69 on May 6, signaling management confidence. Stock at $61.30, down ~25% YTD on healthcare-equipment headwinds. 14 analysts maintain Buy with $81.64 PT.
May 13GE HealthCare insiders bought heavily: Director Larry Culp purchased $5.0M in shares; stock down 23.4% YTD on guidance cut.Positive▶
GE HealthCare directors signaled strong confidence with significant insider buying: Director Lawrence Culp purchased 80,805 shares (~$5.0M) and Director William Stromberg bought 1,000 shares (~$61.7K) on May 6 at $61.69, with no offsetting sales. The stock is down 23.4% YTD trading near $63.29 amid lingering pressure from a prior guidance cut. Management presented at the BofA Health Care Conference on May 12. The annual meeting on May 7 saw eight directors re-elected. The company announced advancements in MR imaging at ISMRM 2026 including Sonic DL 2D imaging. Risk: China demand softness and tariff-related cost pressures on imaging equipment.
May 12GE HealthCare unveiled AI-powered MR systems at ISMRM 2026 May 10-11 including FDA 510(k)-pending Sonic DL deep-learning acceleration; Director Stromberg bought 1,000 shares May 6.Mixed▶
GE HealthCare announced advancements at the ISMRM 2026 Annual Meeting on May 10-11, including next-gen helium-free 1.5T MR, an advanced 3T scanner, and AI-powered workflow. The company announced FDA 510(k) pending status for Sonic DL for 2D imaging beyond cardiac cine, which could benefit up to 85% of MR exams. Two additional installations of the investigational MAGNUS head-only MR prototype were announced at King's College London and West China Hospital. Director Stromberg purchased 1,000 shares at $61.69 on May 6 ($61,689). Management presented at Bank of America's Health Care Conference on May 12. The stock is down roughly 25% YTD. Stock closed at $61.62 on May 11.
May 11GE HealthCare insiders buy near 52-week low after 13% drop on guidance cut and Imaging segment overhaulMixed▶
GE HealthCare reported Q1 2026 revenue of $5.131B with lower net income and reduced FY profit guidance due to tariffs, Patient Care Solutions decline, and a PDx supplier quality issue. Stock fell ~13% with YTD losses near 25%. Management lowered FY adjusted EBIT margin guidance by ~40 bps to 15.4-15.7%. The company combined Imaging and Advanced Visualization units into a new $14.60B Advanced Imaging Solutions segment. On May 6, Director William Stromberg bought 1,000 shares at $61.69 ($61,690); Director Lawrence Culp purchased 80,805 shares ($4,999,405). Pipeline progress includes Phase 2/3 LUMINA trial for manganese-based MRI contrast agent mangaciclanol and Intelerad integration. Annual meeting held May 7. Management presents at BofA Healthcare Conference May 12. 70% of analysts remain bullish.
May 8GE Healthcare reports Q1 2026 revenue of $5.13B with 2.9% organic growth but adjusts EPS guidance lower; combines Imaging and AVS into new Advanced Imaging Solutions segment.Negative▶
GE HealthCare Technologies reported Q1 2026 revenue of $5.131 billion with 2.9% organic growth year-over-year but adjusted EPS of $0.99 fell short of analyst estimates of $1.05. Company announced organizational restructuring combining Imaging and Advanced Visualization Solutions (AVS) into new Advanced Imaging Solutions segment to accelerate innovation. Stock declined 13% on guidance reduction driven by rising input costs and supplier quality issues. Goldman Sachs downgraded rating from Buy to Neutral and cut price target to $65; Mizuho and Evercore ISI also lowered targets. Positive developments include Intelerad acquisition completion, FDA 510(k) clearance for View diagnostic viewer, and AI collaboration with DeepHealth for breast cancer screening. Director H. Lawrence Culp Jr. bought 80,805 shares on May 6 for $5M, signaling insider confidence. Stock down 12.73% over past year.
May 7GE HealthCare Q1 2026 revenue grew 2.9% YoY to $5.1B but profit pressured by inflation and supplier recall, leading to 13% stock decline and reduced guidance.Negative▶
GE HealthCare reported Q1 2026 revenue of $5.1B with 2.9% YoY growth, but earnings and margins were pressured by inflation and a supplier recall, causing 13% stock decline. Management reduced 2026 full-year EPS and margin guidance citing cost headwinds. The company completed the Intelerad acquisition, accelerating cloud-first enterprise solutions and completed FDA approval of next-generation SIGNA MRI technology. GE HealthCare is collaborating with major medical systems to advance AI technology for hospital operations.
May 6GE HealthCare combines Imaging and AVS segments into $14.6B Advanced Imaging Solutions; AI initiatives underwayNeutral▶
GE HealthCare announced executive and operational updates combining Imaging and Advanced Visualization Solutions (AVS) to create Advanced Imaging Solutions (AIS), a $14.6B segment. Q1 revenue grew 2.9% YoY to $5.1B with strong global demand but profit pressured by inflation and supplier recall. Company reduced 2026 EPS and margin guidance but maintains strong sales growth and innovation momentum. GE HealthCare expanding AI capabilities in breast cancer screening through DeepHealth collaboration to improve detection and operational efficiency. New AI solution uses predictive analytics for hospital operational efficiency recommendations. FDA cleared View, next-generation diagnostic viewer for radiologist anywhere-access. Completed Intelerad acquisition accelerating cloud-first enterprise solutions for precision care. Stock down 10.45% over week, 11.98% over month, 12.73% over year. Current price $61.01 with $27.77B market cap. Average analyst rating Buy with 12-month PT $88.38 (48.30% upside). ~53K employees, $19.7B business.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| GEHCGE | $65.35 | +1.58% | +4.6% | 12.0x | 0.87 | $29.3B |
| ISRGINTUITIVE | $416.51 | -5.30% | -0.0% | 37.3x | 1.51 | $155.8B |
| ABTABBOTT | $88.21 | +0.50% | -0.2% | 14.5x | 0.65 | $152.9B |
| SYKSTRYKER | $310.30 | -1.02% | +0.1% | 18.8x | 0.81 | $120.2B |
| MDTMEDTRONIC | $80.25 | +2.69% | +1.1% | 12.9x | 0.63 | $100.3B |
| BSXBOSTON | $47.37 | -17.11% | +2.2% | 15.2x | 0.62 | $84.9B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.